title: sVEGF R1 and Tie-2 levels during chemotherapy of lung cancer patients.
abstract: Angiogenesis plays important role in tumor growth and development. Protein ligands and their receptor tyrosine kinases are crucial in tumor related angiogenesis. Ligand/receptor systems such as vascular endothelial growth factor (VEGF), and tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family play important role in this phenomenon. The aim of this study was to evaluate the concentration of soluble receptor of VEGF (sVEGF R1) and Tie-2 domain in plasma of lung cancer patients before and after chemotherapy. Forty four lung cancer patients, 11 with small lung cancer (SCLC), 5 females and 6 males (mean age 60.2, range 39-72 years), and 33 patients with non-small cell lung cancer (N-SCLC), 6 females and 27 males (mean age 61.9, range 42-78 years) received four courses of chemotherapy. Control group consisted of 44 patients with COPD, 4 females and 40 males (mean age 37.1, 18-60 years). In all cases clinical partial response was achieved. Both sVEGF R1 and Tie-2 concentrations were elevated in cancer group before treatment compared with control: sVEGF (pg/ml): 60.7 and 66.2 vs. 48.8 and Tie-2 (ng/ml): 37.3 and 37.5 vs. 30.7 in SCLC and N-SCLC vs. C, respectively. Treatment decreased sVEGF R1 (pg/ml): 66.7 vs. 11.6 (p < 0.05) and 66.2 vs. 14.39 (p < 0.001), and Tie-2 (ng/ml): 37.3 vs. 26.3 (p < 0.05) and 37.5 vs. 25.7 (p < 0.001) in SCLC and N-SCLC, respectively. We conclude that VEGF R1and Tie-2 receptors may play important role in lung cancer development and their receptor concentrations may reflect the patients' response to treatment.
authors: Department of Lung Diseasess, Bialystok Medical University, Bialystok, Poland. robmroz@wp.pl
authors: R M
authors: RM
authors: Mroz
authors: M
authors: M
authors: Korniluk
authors: B
authors: B
authors: Panek
authors: M
authors: M
authors: Ossolinska
authors: E
authors: E
authors: Chyczewska
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D002945:Cisplatin / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood; D042787:Receptor, TIE-2 / Q000097:blood*; D016896:Treatment Outcome; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000097:blood*; D000093542:Gemcitabine
chemical_list: D014408:Biomarkers, Tumor; D003841:Deoxycytidine; D005047:Etoposide; D042787:Receptor, TIE-2; D040281:Vascular Endothelial Growth Factor Receptor-1; D002945:Cisplatin; D000093542:Gemcitabine